KR102234310B1 - COMPOSITION COMPRISING Machilus thunbergii FOR PREVENTING, IMPROVING OR TREATING ORAL DISEASE - Google Patents

COMPOSITION COMPRISING Machilus thunbergii FOR PREVENTING, IMPROVING OR TREATING ORAL DISEASE Download PDF

Info

Publication number
KR102234310B1
KR102234310B1 KR1020190086280A KR20190086280A KR102234310B1 KR 102234310 B1 KR102234310 B1 KR 102234310B1 KR 1020190086280 A KR1020190086280 A KR 1020190086280A KR 20190086280 A KR20190086280 A KR 20190086280A KR 102234310 B1 KR102234310 B1 KR 102234310B1
Authority
KR
South Korea
Prior art keywords
oral
active ingredient
present
composition
atcc
Prior art date
Application number
KR1020190086280A
Other languages
Korean (ko)
Other versions
KR20210009583A (en
Inventor
서정훈
신동규
차정단
고은실
조상민
정지혜
정종훈
강제란
차수미
Original Assignee
제너럴바이오(주)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 제너럴바이오(주) filed Critical 제너럴바이오(주)
Priority to KR1020190086280A priority Critical patent/KR102234310B1/en
Publication of KR20210009583A publication Critical patent/KR20210009583A/en
Application granted granted Critical
Publication of KR102234310B1 publication Critical patent/KR102234310B1/en

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/54Lauraceae (Laurel family), e.g. cinnamon or sassafras
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • A61K31/43Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783Angiosperms [Magnoliophyta]
    • A61K8/9789Magnoliopsida [dicotyledons]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/005Antimicrobial preparations

Abstract

본 발명은 후박나무를 유효성분으로 포함하는 구강질환의 예방, 개선 또는 치료용 조성물에 관한 것으로, 후박나무(Trichosanthes kirilowii) 추출물을 유효성분으로 포함하여 구강질환의 예방 또는 치료용 약학적 조성물을 제공한다.
또한, 본 발명은 후박나무(Trichosanthes kirilowii) 추출물을 유효성분으로 포함하여 구강질환의 예방 또는 개선용 구강위생 조성물을 제공한다.
이에 따라 본 발명은 구강질환 유발균주에 대한 생장억제 활성을 나타내므로, 이를 유효성분으로 포함하는 의약품은 치아우식증 및 치주질환 등의 구강질환을 예방 및 치료할 수 있는 효과가 있다. 특히, 본 발명에 따른 천연추출물을 치약, 구강청정제 등으로 사용하는 경우, 구강병원균의 생장과 활성을 억제하여 세균침전물인 치태의 형성을 효과적으로 예방할 수 있는 효과가 있다. 또한, 본 발명에 따른 천연추출물은 안전성이 입증된 천연물을 유효성분으로 사용하므로 부작용이 극히 적은 장점이 있다.
The present invention relates to a composition for the prevention, improvement, or treatment of oral diseases comprising Hubak tree as an active ingredient, and provides a pharmaceutical composition for the prevention or treatment of oral diseases, including the extract of Hubak tree (Trichosanthes kirilowii) as an active ingredient. do.
In addition, the present invention provides an oral care composition for the prevention or amelioration of oral disease including magnolia (Trichosanthes kirilowii) extract as an active ingredient.
Accordingly, since the present invention exhibits a growth inhibitory activity against oral disease-causing bacteria, a drug containing this as an active ingredient has an effect of preventing and treating oral diseases such as dental caries and periodontal disease. In particular, when the natural extract according to the present invention is used as a toothpaste, mouthwash, etc., there is an effect of effectively preventing the formation of plaque, which is a bacterial precipitate, by inhibiting the growth and activity of oral pathogens. In addition, the natural extract according to the present invention has the advantage of having very few side effects since it uses a natural product with proven safety as an active ingredient.

Description

후박나무를 유효성분으로 포함하는 구강질환의 예방, 개선 또는 치료용 조성물 {COMPOSITION COMPRISING Machilus thunbergii FOR PREVENTING, IMPROVING OR TREATING ORAL DISEASE}Composition for the prevention, improvement or treatment of oral diseases that contain the red oak as an active ingredient {COMPOSITION COMPRISING Machilus thunbergii FOR PREVENTING, IMPROVING OR TREATING ORAL DISEASE}

본 발명은 후박나무를 유효성분으로 포함하는 구강질환의 예방, 개선 또는 치료용 조성물에 관한 것으로, 후박나무 추출물을 이용하여 각종 구강질환을 예방, 개선 또는 치료할 수 있는 약학적 조성물 및 구강위생 조성물에 관한 것이다.The present invention relates to a composition for the prevention, improvement, or treatment of oral diseases comprising a red oak as an active ingredient, and a pharmaceutical composition and oral hygiene composition capable of preventing, improving or treating various oral diseases using a red oak extract About.

구강 질환은 치아 우식증과 치주질환의 주요한 건강 문제로서 예방할 수 있는 중요한 전염성 질병이다. 구강 건강은 전반적인 삶의 질에 영향을 미치는데, 구강 건강을 소홀히 할 경우 만성 질환이나 전신 질환으로 이어질 수 있다. 구강 내 바이오필름(biofilm)이 발달함에 따라 Lactobacillus casei, Streptococcus sanguis, Streptococcus mutans, Streptococcus mitis Streptococcus sobrinus와 같은 미생물이 발생할 수 있고, 이는 치아의 법랑질(enamel)과 잇몸 조직의 손상의 원인이 된다. 구강 질환은 이러한 바이오필름의 생성에 따라 구강 내 생태계의 평형이 무너짐으로써 발생하기 때문에, 바이오필름의 기계적인 제거는 충치와 치주 질환 예방에 중요한 역할을 한다.Oral disease is an important infectious disease that can be prevented as a major health problem of dental caries and periodontal disease. Oral health affects your overall quality of life, and neglect of oral health can lead to chronic or systemic disease. As the biofilm in the oral cavity develops, microorganisms such as Lactobacillus casei , Streptococcus sanguis , Streptococcus mutans , Streptococcus mitis, and Streptococcus sobrinus may occur, which causes damage to tooth enamel and gum tissue. Since oral diseases are caused by collapsing the equilibrium of the oral ecosystem according to the production of such biofilms, mechanical removal of biofilms plays an important role in preventing tooth decay and periodontal disease.

충치의 발달은 그람양성(gram-positive)의 산생성균(acidogenic bacteria)이나 내산성균(acidoduric bacteria)과 밀접한 관련이 있는데, 주로 mutans streptococci(S. mutansS. sobrinus을 말함), lactobacilli 및 actinomycetes이 이에 해당한다. 이들 세균은 대사과정을 통해 수크로스(sucrose)를 젖산과 같은 유기산으로 바꾸고, 산은 치아의 인산칼슘(calcium phosphate)를 녹임으로써 충치가 발생한다.The development of caries is closely related to gram-positive acidogenic or acidoduric bacteria, mainly mutans streptococci ( referring to S. mutans and S. sobrinus ), lactobacilli and actinomycetes. Corresponds to this. These bacteria transform sucrose into organic acids such as lactic acid through metabolic processes, and the acid dissolves calcium phosphate in teeth, causing tooth decay.

전술한 바와 같이 플라크 형성에 핵심적인 역할을 하는 불용성 글루칸이 지속적으로 축적되어 필름 형태의 얇은 막으로 형성되는 바이오필름은, 세균이 치아에 부착되거나 세균들 간의 응괴(凝塊, 응고된 덩어리)에 큰 도움을 주어 결과적으로 치태를 형성시키는 바, 치아우식 및 치주질환 등의 구강질병 유발에 크게 영향을 미친다. 또한, 세균 응괴(凝塊) 형태로 형성된 바이오 필름은 치아 부착 이외에도 식도 등을 따라 몸 전체로 전이되어 심혈관계 질환 및 체내 염증성 질병을 유발하는 것으로 알려져 있다.As described above, the biofilm, which is formed into a thin film in the form of a film by continuously accumulating insoluble glucan, which plays a key role in plaque formation, prevents bacteria from adhering to teeth or coagulation (coagulated mass) between bacteria. It is a great help to form plaque as a result, and it greatly affects the induction of oral diseases such as dental caries and periodontal disease. In addition, the biofilm formed in the form of a bacterial clot is known to be transferred to the entire body along the esophagus, etc. in addition to tooth attachment, causing cardiovascular disease and inflammatory diseases in the body.

이에 따라 치아우식증 및 치주질환을 예방하거나 치료하기 위하여 구강 내 연쇄상구균(streptococci)을 억제하는 것이 필요하다. 구강질환을 부작용 없이 안전하게 치료하기 위해 최근에는 천연물로부터 추출된 물질을 바탕으로 한 연구가 진행되고 있다. 그 중 한 연구결과에 따르면 아스퍼질러스 테레우스(Aspergillus terreus)의 배양액에서 분리된 뮤타스테인(mutastein)이 스트렙토코커스 뮤탄스의 글루코실트랜스퍼라이제 활성을 억제하여 불용성 글루칸의 합성과 부착을 억제한다는 보고가 있다.Accordingly, it is necessary to suppress streptococci in the oral cavity in order to prevent or treat dental caries and periodontal diseases. In order to safely treat oral diseases without side effects, research is being conducted based on substances extracted from natural products. One study found that mutastein isolated from the culture of Aspergillus terreus inhibited the glucosyltransferase activity of Streptococcus mutans, thereby inhibiting the synthesis and adhesion of insoluble glucans. There is a report.

‘특허문헌 1’은 혼합 추출물을 함유하는 치주질환 예방 또는 치료용 조성물에 관한 것으로 생지황, 현삼, 및 옥수수 속대의 혼합 추출물을 함유하는 치주질환 예방 또는 치료용 조성물을 제공한다. 또 다른 기술문헌인 ‘특허문헌 2’는 천일염, 천년초, 민트, 녹차, 월계수 잎을 사용한 천연물 구강제 조성물에 관한 것이다. 'Patent Document 1'relates to a composition for preventing or treating periodontal diseases containing a mixed extract, and provides a composition for preventing or treating periodontal diseases containing a mixed extract of saengjihwang, hyeonsam, and corncobs. Another technical document,'Patent Document 2', relates to a natural oral composition using sea salt, cheonnyeoncho, mint, green tea, and laurel leaves.

그러나 치아우식증 및 치주질환에 효과를 나타내는 종래의 천연추출물은 항균성만을 발휘하거나 또는 바이오필름을 생성시키는 효소의 형성 억제 활성만을 발휘하는 등 각각에 대해서만 기능을 하기 때문에 구강질환을 효율적으로 예방하거나 치료할 수 없는 문제점이 있다.However, conventional natural extracts that have an effect on dental caries and periodontal diseases can effectively prevent or treat oral diseases because they function only for each of them, such as exhibiting only antibacterial activity or only exhibiting the activity of inhibiting the formation of enzymes that produce biofilms. There is no problem.

KR 10-2019-0000955 A1 (2019. 01. 04.)KR 10-2019-0000955 A1 (2019.01.04.) KR 10-2015-0027352 A2 (2015. 03. 12.)KR 10-2015-0027352 A2 (2015.03.12.)

본 발명은 위와 같은 문제점을 해결하기 위하여 안출된 것으로, 본 발명에서 해결하고자 하는 과제는 항균성을 갖음과 동시에 바이오필름의 생성을 억제할 수 있는 천연추출물을 이용하는 후박나무(Machilus thunbergii)를 유효성분으로 포함하는 구강질환의 예방, 개선 또는 치료용 조성물을 제공하는 것이다.The present invention has been conceived to solve the above problems, and the problem to be solved in the present invention is to have antimicrobial properties and at the same time use a natural extract capable of suppressing the production of biofilms, Machilus thunbergii , as an active ingredient. It is to provide a composition for preventing, improving or treating oral diseases, including.

위와 같은 과제를 해결하기 위한 본 발명은 후박나무(Machilus thunbergii) 추출물을 유효성분으로 포함하는 구강질환의 예방, 개선 또는 치료용 조성물을 제공하는 것을 기술적 특징으로 한다.The present invention for solving the above problems is a technical feature to provide a composition for preventing, improving or treating oral diseases comprising an extract of Machilus thunbergii as an active ingredient.

또한 위와 같은 과제를 해결하기 위한 본 발명은 후박나무 추출물을 유효성분으로 포함하는 구강질환의 예방 또는 개선용 구강위생 조성물을 제공하는 것을 기술적 특징으로 한다.In addition, the present invention for solving the above problems is a technical feature to provide an oral hygiene composition for the prevention or improvement of oral diseases comprising the extract as an active ingredient.

본 발명은 구강질환 유발균주에 대한 생장억제 활성을 나타내므로, 이를 유효성분으로 포함하는 의약품은 치아우식증 및 치주질환 등의 구강질환을 예방 및 치료할 수 있는 효과가 있다.Since the present invention exhibits a growth inhibitory activity against an oral disease-causing strain, a pharmaceutical product containing it as an active ingredient has the effect of preventing and treating oral diseases such as dental caries and periodontal disease.

특히, 본 발명에 따른 천연추출물을 치약, 구강청정제 등으로 사용하는 경우, 구강병원균의 생장과 활성을 억제하여 세균침전물인 치태의 형성을 효과적으로 예방할 수 있는 효과가 있다.In particular, when the natural extract according to the present invention is used as a toothpaste, mouthwash, etc., there is an effect of effectively preventing the formation of plaque, which is a bacterial precipitate, by inhibiting the growth and activity of oral pathogens.

또한, 본 발명에 따른 천연추출물은 안전성이 입증된 천연물을 유효성분으로 사용하므로 부작용이 극히 적은 장점이 있다.In addition, the natural extract according to the present invention has the advantage of having very few side effects since it uses a natural product with proven safety as an active ingredient.

도 1 내지 3은 후박나무 에탄올 추출물과 앰피실린 또는 후박나무 에탄올 추출물과 겐타마이신을 시간-사멸 및 생장 억제 곡선 결과를 나타낸 그래프1 to 3 is a graph showing the results of time-kill and growth inhibition curves of the Ethanol extract and Ampicillin or Ethanol Extract and Gentamicin

본 명세서 및 청구범위에 사용된 용어나 단어는 "발명자는 그 자신의 발명을 가장 최선의 방법으로 설명하기 위해 용어의 개념을 적절하게 정의할 수 있다는 원칙"에 입각하여 본 발명의 기술적 사상에 부합하는 의미와 개념으로 해석되어야지, 통상적이거나 사전적인 의미로 한정해서 해석되서는 안 된다.Terms and words used in the present specification and claims conform to the technical idea of the present invention based on the principle that "the inventor can appropriately define the concept of terms in order to describe his or her invention in the best way." It should be construed as a meaning and concept, but not limited to a conventional or dictionary meaning.

따라서 본 명세서에 기재된 실시예와 도면에 도시된 구성은 본 발명의 가장 바람직한 실시예에 불과할 뿐이고, 본 발명의 기술적 사상을 모두 대변하는 것은 아니므로, 본 출원시점에 있어서 이들을 대체할 수 있는 다양한 균등물과 변형 예들이 있을 수 있음을 이해해야 한다.Therefore, the embodiments described in the present specification and the configurations shown in the drawings are only the most preferred embodiments of the present invention, and do not represent all the technical spirit of the present invention, and thus various equivalents that can replace them at the time of application It should be understood that there may be water and variations.

후박나무(Machilus thunbergii)는 높이 20m 정도로 자라며 수피는 갈색으로 껍질눈이 있으며 어린가지는 녹색을 띤다. 노목은 수피가 비늘조각처럼 떨어진다. 어긋나게 달리는 잎은 가지 끝에서는 돌려난 것처럼 보이며 도란형 또는 장타원형으로 가장자리는 밋밋하다. 표면은 녹색이고 질이 두꺼우며 양면에 털이 없다. 잎자루는 길이 2~3cm 정도로 굵은 편이다. 꽃은 양성화로 5~6월에 잎겨드랑이에서 나온 원추화서에 황록색의 꽃이 핀다. 열매는 장과로 둥글고 이듬해 7~9월에 흑자색으로 익는다. 후박나무는 한국이 원산지로 울릉도와 남부지방의 바닷가의 산기슭에서 자라는 상록활엽교목이다. 추위에 약하지만 내조성이 강하여 비옥한 해안지방에서 잘 생육한다. Machilus thunbergii (Machilus thunbergii) grows up to 20m in height. The bark is brown with bark eyes and the young branches are green. The bark of the old tree falls like a piece of scale. Leaves that run alternately appear to be turned at the ends of the branches, obovate or oblong, and have a flat edge. The surface is green and the quality is thick, and there are no hairs on both sides. The petiole is thick, about 2~3cm long. The flowers are bisexual, and yellow-green flowers bloom on the conical inflorescences from the axils from May to June. Fruits are berry, round, and ripen in black purple in July-September of the following year. Hubak tree is an evergreen broad-leaved arboreous tree that is native to Korea and grows at the foot of a mountain in the southern part of Ulleungdo. It is weak against cold but has strong composition resistance and grows well in fertile coastal areas.

후박나무의 피질은 예로부터 약재로서 다리의 부종이나 복부 팽만 및 통증에 사용되어 왔다. 후박나무의 뿌리(root)에는 아이소퀴놀린 알칼로이드(isoquinoline alkaloids)가 존재하고, 심재(heartwood)에는 리그닌(lignin), 카테킨(catechin) 및 폴리사카라이드(polysaccharides)가 존재하며, 잎에는 에센셜오일(essential oils)이, 과일에는 휘발성 성분이, 피질(cortex)에는 리그난(lignans)과 네오리그난(neolignans)이 존재하는 것으로 알려져 있다.Since ancient times, the cortex has been used as a medicinal for leg swelling, abdominal distension, and pain. Isoquinoline alkaloids are present in the root of the black oak tree, lignin, catechin, and polysaccharides are present in the heartwood, and essential oil (essential oil) is present in the leaves. oils), volatile components in fruits, and lignans and neoignans in the cortex are known.

본 발명은 후박나무 에탄올 추출물(Machilus thunbergii ethanol extract, MTEE)을 주성분으로 한 구강 병원균에 항균활성을 지닌 구강질환 예방 및 치료용 약학적 조성물에 관한 것이다. 본 발명의 후박나무 에탄올 추출물은 단독으로도 사용 가능하지만, 항생제와 함께 사용할 경우 더욱 우수한 구강 병원균에 항균활성 및 항바이오 필름활성을 나타낸다.The present invention relates to a pharmaceutical composition for the prevention and treatment of oral diseases having antibacterial activity against oral pathogens containing Machilus thunbergii ethanol extract (MTEE) as a main component. The ethanol extract of the present invention can be used alone, but when used together with an antibiotic, it exhibits more excellent antibacterial activity and anti-biofilm activity against oral pathogens.

이하에서 설명할 실험은 각 실험예마다 세 번씩 실시하였고, 통계 분석은 상용 소프트웨어(SPSS 22.0)를 사용하여 매개 변수 검정(양방향 분산 분석[ANOVA], parametric tests)으로 수행되었고, 그 결과를 평균값 ±표준 편차로 표현하되, p <0.05 수준에서 유의하다고 간주하였다.Experiments to be described below were performed three times for each experimental example, and statistical analysis was performed by parameter tests (two-way analysis of variance [ANOVA], parametric tests) using commercial software (SPSS 22.0), and the results were averaged ± Expressed as standard deviation, but considered significant at the p <0.05 level.

실시예. 후박나무 에탄올 추출물의 제조Example. Preparation of Ethanol Extract of Blackberry

건조된 후박나무 줄기 200g을 분쇄하여 80% 농도의 에탄올을 10배의 부피량으로 넣어 120℃의 온도로 24시간 반응시켜 액체층만을 회수하여 추출하였다. 추출액은 다시 워터만 종이 여과지로 감압 여과한 후, 남은 고형분을 제거하고 나머지 액을 냉각 콘덴서가 달린 농축장치에서 감압 농축하여 동결 건조하여 농도 80 brix의 추출액을 제조하였다.200 g of dried black oak trunks were pulverized, ethanol of 80% concentration was added in a volume of 10 times and reacted at a temperature of 120° C. for 24 hours to recover and extract only the liquid layer. The extract was again filtered under reduced pressure with only water paper filter paper, and the remaining solids were removed, and the remaining liquid was concentrated under reduced pressure in a concentrator equipped with a cooling condenser and freeze-dried to prepare an extract having a concentration of 80 brix.

실험예 1. 최소억제농도/최소살균농도 분석(Minimum inhibitory concentrations/minimum bactericidal concentrations assay, MIC/MBC assay)Experimental Example 1. Minimum inhibitory concentration / minimum bactericidal concentration analysis (Minimum inhibitory concentrations/minimum bactericidal concentrations assay, MIC/MBC assay)

1-1. 실험 준비1-1. Preparation for experiment

본 실험에 사용된 우식유발성 세균(cariogenic bacteria)은 Streptococcus mutans ATCC 25175, Streptococcus sanguinis ATCC 10556, Streptococcus sobrinus ATCC 27607, Streptococcus ratti KCTC 3294, Streptococcus criceti KCTC 3292, Streptococcus anginosus ATCC 31412, Streptococcus gordonii ATCC 10558이다.The dental caries-inducing bacteria (cariogenic bacteria) used in this study is the Streptococcus mutans ATCC 25175, Streptococcus sanguinis ATCC 10556, Streptococcus sobrinus ATCC 27607, Streptococcus ratti KCTC 3294, Streptococcus criceti KCTC 3292, Streptococcus anginosus ATCC 31412, Streptococcus gordonii ATCC 10558.

또한, 본 실험에 사용된 치주병원성 세균(periodontopathogenic bacteria)은 Aggregatibacter actinomycetemcomitans ATCC 43717, Fusobacterium nucleatum ATCC 51190, Prevotella intermedia ATCC 49046 및 Porphylomonas gingivalis ATCC 33277이다.In addition, periodontopathogenic bacteria used in this experiment were Aggregatibacter actinomycetemcomitans ATCC 43717, Fusobacterium nucleatum ATCC 51190, Prevotella intermedia ATCC 49046 and Porphylomonas gingivalis ATCC 33277.

여기서 KCTC는 Korean collection for type culture의 약자이며, ATCC는 American type culture collection의 약자이다.Here, KCTC stands for Korean collection for type culture, and ATCC stands for American type culture collection.

Prevotella intermedia ATCC 49046 및 Porphylomonas gingivalis ATCC 33277 등 두 구강병원균을 제외한 나머지에는 Brain-Heart Infusion(Difco Laboratories, Detroit, MI) 배지에 1%의 yeast extract(Difco)가 첨가된 것을 사용하였고, Prevotella intermedia ATCC 49046 및 Porphylomonas gingivalis ATCC 33277에는 BHI 배지에 1㎍/㎖의 hemin(Sigma, St. Louis, MO, USA) 및 1㎍/㎖의 menadione이 첨가된 것을 사용하였다. Excluding two oral pathogens such as Prevotella intermedia ATCC 49046 and Porphylomonas gingivalis ATCC 33277, 1% yeast extract (Difco) was added to Brain-Heart Infusion (Difco Laboratories, Detroit, MI) medium, and Prevotella intermedia ATCC 49046. And Porphylomonas gingivalis ATCC 33277 were used in BHI medium to which 1 μg/ml of hemin (Sigma, St. Louis, MO, USA) and 1 μg/ml of menadione were added.

1-2. 실험 과정1-2. Experimental process

실시예를 통해 제조된 후박나무 에탄올 추출물을 액체희석배양법(broth dilution method)에 의해 최소억제농도를 측정하였고, 이를 3회 반복 실시하였다.The minimum inhibitory concentration was measured by the broth dilution method of the ethanol extract of Hubak tree prepared through the examples, and this was repeated three times.

실험예 1-1의 과정으로 배양된 11가지의 구강병원균들을 37℃에서 혐기성 조건에서 배양했다. 통성 혐기성균(facultative anaerobic bacteria)은 18시간, 미호기성균microaerophilic bacteria)은 24시간, 절대 혐기성균(obligate anaerobic bacteria)은 1-2일 동안 배양했다. 11 oral pathogens cultured in the process of Experimental Example 1-1 were cultured at 37° C. under anaerobic conditions. Facultative anaerobic bacteria were cultured for 18 hours, microaerophilic bacteria for 24 hours, and obligate anaerobic bacteria for 1-2 days.

최소억제농도(MIC)는 배지에서 완전히 가시적인 성장을 저해하는 시험샘플의 최저 농도로 결정했다. 구강 세균의 50 % 및 90 %가 억제 된 농도를 각각 MIC 50 및 MIC 90 으로 표기하였다. 최소살균농도(MBC)는 시험균의 99.9%가 사멸될 때의 후박 나무의 에탄올 추출물의 최소 농도로 결정했다. The minimum inhibitory concentration (MIC) was determined as the lowest concentration of the test sample that completely inhibited visible growth in the medium. The concentrations at which 50% and 90% of oral bacteria were inhibited were expressed as MIC 50 and MIC 90 , respectively. The minimum sterilization concentration (MBC) was determined as the minimum concentration of the ethanol extract of Humpback when 99.9% of the test bacteria were killed.

구강 세균에 대한 후박나무 에탄올 추출물의 민감도(sensitivity)를 비교하기 위해 앰피실린과 겐타마이신(시그마)을 표준 항생제로 사용했다.Ampicillin and gentamicin (Sigma) were used as standard antibiotics to compare the sensitivity of the ethanol extract of H. mulberry to oral bacteria.

1-3. 실험결과1-3. Experiment result

표 1은 구강병원균에 대한 후박나무 에탄올 추출물의 최소억제농도(MIC) 및 최소살균농도(MBC)를 나타낸 결과이다.Table 1 shows the results showing the minimum inhibitory concentration (MIC) and the minimum sterilization concentration (MBC) of the ethanol extract of Hubak tree against oral pathogens.

Figure 112019073192859-pat00001
Figure 112019073192859-pat00001

표 1을 참조하면, 항균활성결과 후박나무 에탄올 추출물(MTEE)은 우식유발성 세균(MICs, 12.5 에서 50 ㎍/㎖; MBSs, 50 에서 200 ㎍/㎖), 치주병원성 세균(MICs, 25 에서 50 ㎍/㎖;MBSs, 50 에서 200 ㎍/㎖)에 대해 항균활성을 보였다. 앰피실린은 0.0625/8-0.0125/32 ㎍/㎖에서 활성을 보인 반면, 겐타마이신은 4/8-128/512 ㎍/㎖에서 활성을 보였다. MIC50과 MIC90의 범위는 각각 3.13에서 12.5 ㎍/㎖ 및 12.5에서 50 ㎍/㎖ 범위에서 활성을 보였다.Referring to Table 1, the results of antibacterial activity and ethanol extract (MTEE) from Mumbai were caries-causing bacteria (MICs, 12.5 to 50 μg/mL; MBSs, 50 to 200 μg/mL), periodontal pathogenic bacteria (MICs, 25 to 50). It showed antimicrobial activity against μg/ml; MBSs, 50 to 200 μg/ml). Ampicillin showed activity at 0.0625/8-0.0125/32 µg/ml, while gentamicin showed activity at 4/8-128/512 µg/ml. The ranges of MIC 50 and MIC 90 showed activity in the ranges of 3.13 to 12.5 µg/ml and 12.5 to 50 µg/ml, respectively.

후박나무 에탄올 추출물은 특히 다른 구강병원균(MIC/MBC, 25/50-50/200 ㎍/㎖) 보다 S. gordonii ATCC 10558(MIC/MBC, 12.5/50 ㎍/㎖)에 대해서 강력한 항균활성을 보여줬다. 즉, MIC50 및 MIC90이 각각 3.13 ㎍/㎖ 및 12.5 ㎍/㎖로 최저 농도를 보여줬다. Ethanol extract of H. mulberry showed strong antimicrobial activity against S. gordonii ATCC 10558 (MIC/MBC, 12.5/50 μg/ml) than other oral pathogens (MIC/MBC, 25/50-50/200 μg/ml). . That is, MIC 50 and MIC 90 showed the lowest concentrations of 3.13 µg/ml and 12.5 µg/ml, respectively.

실험예 2. 체커보드 희석 테스트(Checker-board dilution test)Experimental Example 2. Checker-board dilution test

2-1. 실험 준비2-1. Preparation for experiment

실험예 1-1과 동일한 과정으로 실행하였다.It was carried out in the same procedure as in Experimental Example 1-1.

2-2. 실험 과정2-2. Experimental process

상승작용(synergistic effect)은 서로 다른 두 가지의 약물을 어느 정도 용량 내에서 동시에 투여했을 때의 약효가 각각의 약을 단독으로 투여했을 때의 약효를 더한 것보다 강한 작용이 나타나는 현상이며, 상가작용(additive effect)은 서로 다른 두 가지 약물을 어느 정도 용량 내에서 동시에 투여했을 때의 약효와 각각의 약을 단독으로 투여했을 때 약효를 더한 것과 같거나 유사한 현상이다. 본 발명에서는 항균활성의 상승작용을 확인하기 위하여 앰피실린 또는 겐타마이신을 함께 사용하였다.Synergistic effect is a phenomenon in which the drug effect when two different drugs are administered simultaneously within a certain dose is stronger than that when each drug is administered alone. (additive effect) is a phenomenon that is the same as or similar to the drug effect when two different drugs are administered simultaneously within a certain amount of the drug and the drug effect when each drug is administered alone. In the present invention, ampicillin or gentamicin was used together to confirm the synergistic effect of antimicrobial activity.

FICI(fractional inhibitory concentration index, 부분 억제 농도 지수)는 가장 효과적인 조합에서의 FIC(fractional inhibitory concentration, 부분 억제 농도) 값의 합으로, 항생제 병용 효과의 연구결과 해석 시에 가장 일반적으로 사용한다. The fractional inhibitory concentration index (FICI) is the sum of the fractional inhibitory concentration (FIC) values in the most effective combination, and is most commonly used when interpreting the results of studies of antibiotic combination effects.

수학식 1은 FIC의 계산법이다.Equation 1 is a calculation method of FIC.

Figure 112019073192859-pat00002
Figure 112019073192859-pat00002

(A)는 약물 A와 병용으로 사용하고자 하는 약물을 병용 사용했을 때의 MIC를 의미하고, MICA는 약물 A를 단독으로 사용했을 때의 MIC를 의미한다.(A) means the MIC when a drug to be used in combination with drug A is used in combination, and MIC A refers to the MIC when drug A is used alone.

수학식 2는 FICI의 계산법이다.Equation 2 is a calculation method of FICI.

Figure 112019073192859-pat00003
Figure 112019073192859-pat00003

(A)는 약물 A와 병용으로 사용하고자 하는 약물을 병용 사용했을 때의 MIC를 의미하고, MICA는 약물 A를 단독으로 사용했을 때의 MIC를 의미하고, (B)는 약물 B와 병용으로 사용하고자 하는 약물을 병용 사용했을 때의 MIC를 의미하고, MICB는 약물 B를 단독으로 사용했을 때의 MIC를 의미한다.(A) refers to the MIC when a drug to be used in combination with drug A is used in combination, MIC A refers to the MIC when drug A is used alone, and (B) is used in combination with drug B. It means the MIC when the drug to be used is used in combination, and MIC B means the MIC when the drug B is used alone.

그리고 FBC(fractional bactericidal concentration, 부분 살균 농도)는 FIC의 계산법과 동일하게 하고, FBCI(fractional bactericidal concentration index, 부분 살균 농도 지수)는 FICB의 계산법과 동일하게 하되, MIC값이 아닌 MBC값으로 대체하여 계산한다. FBCI는 가장 효과적인 조합에서의 FBC의 값의 합이다.In addition, the fractional bactericidal concentration (FBC) is the same as the calculation method of FIC, and the fractional bactericidal concentration index (FBCI) is the same as the calculation method of FICB. Calculate. FBCI is the sum of the values of FBC in the most effective combination.

FICI 및 FBCI값이 0.5이하면 항균활성에 있어서 후박나무 에탄올 추출물과 항생제의 조합에 따른 상승작용(synergistic effect)이 있는 것으로 간주하여 ‘상승’으로 표시하였고, 0.5초과 1.0이하 일 경우 단순히 첨가량에 따른 농도 의존적인 효과, 즉 상가작용만을 나타낸다고 판단하여 ‘상가’로 표시하였다. 만약 1.0 초과 2.0 이하일 경우 상호작용이 없는 것(indiffernt)으로, 2.0을 초과하는 경우에는 적대적인 것(antagonistic)으로 판단하였다.If the FICI and FBCI values are less than 0.5, it is considered that there is a synergistic effect according to the combination of the ethanol extract and antibiotics of H. It was judged to show only the concentration-dependent effect, that is, additive action, and marked as'additional value'. If it is more than 1.0 and less than 2.0, it is considered to be indiffernt, and if it is more than 2.0, it is considered to be antagonistic.

체커보드 희석 테스트를 통해 후박나무 에탄올 추출물과 항생제의 조합으로 항균효과를 확인하였다. 두 가지 다른 항생제(Ampicillin 및 Gentamicin)의 연속 희석액(serial dilution)을 양이온이 보충된 뮐러 - 힌튼 (Mueller-Hinton) 배지에서 혼합하였다. 그런 다음 11가지 구강병원균을 37 ℃에서 24-48 시간 배양한 후, 가시적인 성장이 멈추는 최소의 농도를 최소억제농도(MIC)로 결정하였고, 시험균의 99.9%가 사멸되는 최소한의 농도를 최소살균농도(MBC)로 결정하였다. 그 결과를 표 2(앰피실린) 및 표 3(겐타마이신)을 통해 도시하였다. Through the checkerboard dilution test, the antibacterial effect was confirmed by the combination of the ethanol extract and antibiotics. Serial dilutions of two different antibiotics (Ampicillin and Gentamicin) were mixed in a cation-supplemented Mueller-Hinton medium. Then, after incubating 11 oral pathogens at 37°C for 24-48 hours, the minimum concentration at which visible growth stops was determined as the minimum inhibitory concentration (MIC), and the minimum concentration at which 99.9% of the test bacteria are killed is the minimum. It was determined by sterilization concentration (MBC). The results are shown in Table 2 (Ampicillin) and Table 3 (Gentamicin).

표 2 및 3에서 ‘단독’은 시약을 단독으로 사용한 것을 의미하며 ‘조합’은 항생제와의 조합된 것을 사용한 것을 의미한다. FIC 및 FBC는 "(조합 후 사용량)/(조합 전 사용량)"을 의미한다. In Tables 2 and 3, “alone” means using a reagent alone, and “combination” means using a combination with antibiotics. FIC and FBC mean "(amount after combination)/(amount before combination)".

2-3. 실험결과2-3. Experiment result

표 2는 구강병원균에 대한 후박나무 에탄올 추출물과 앰피실린의 체커보드 희석테스트 결과이다.Table 2 shows the results of a checkerboard dilution test of ethanol extract and ampicillin from Humbak tree against oral pathogens.

Figure 112019073192859-pat00004
Figure 112019073192859-pat00004

후박나무 에탄올 추출물과 앰피실린이 조합된 경우 MIC가 4배 이상 감소되는 것을 알 수 있다. It can be seen that the MIC is reduced by more than 4 times when the ethanol extract of H. mulberry and ampicillin are combined.

또한 S. gordonii를 제외한 나머지 구강병원균에서 FICI가 0.5 이하로 확인되었으며 이에 따라 상승작용이 발생하는 것을 알 수 있다. 다만, S. gordonii의 경우에는 FICI가 0.75이하로 상가작용이 발생하는 것을 알 수 있다. In addition, FICI was confirmed to be less than 0.5 in the other oral pathogens except S. gordonii, and it can be seen that synergy occurs accordingly. However, in the case of S. gordonii , it can be seen that additive action occurs with FICI less than 0.75.

또한, 앰피실린이 조합된 경우 S. ratti, S. criceti, P. gingivalis를 제외한 모든 구강병원균에서 FBCI가 0.5이하로 측정되어 상승작용이 발생하는 것을 알 수 있다.In addition, when ampicillin was combined, FBCI was measured to be 0.5 or less in all oral pathogens except S. ratti, S. criceti, and P. gingivalis, indicating that a synergistic effect occurs.

Figure 112019073192859-pat00005
Figure 112019073192859-pat00005

표 3은 구강병원균에 대한 후박나무 에탄올 추출물과 겐타마이신의 체커보드 희석테스트 결과이다.Table 3 shows the results of a checkerboard dilution test of ethanol extract and gentamicin of H. oak tree against oral pathogens.

겐타마이신이 조합된 경우 S. criceti, P. gingivalis를 제외한 모든 구강병원균에서 MIC가 4 내지 8배 이상 감소함을 알 수 있고, FICI는 0.5이하로서 상승작용을 하는 것을 알 수 있다. 그리고 S. sanguinis, S. ratti, S .anginosus, F. nucleatum을 제외한 나머지 모든 구강병원균에서 FBCI가 0.5이하로서 상승작용을 하는 것을 알 수 있다.When gentamicin is combined, it can be seen that MIC is reduced by 4 to 8 times or more in all oral pathogens except S. criceti and P. gingivalis, and FICI is less than 0.5, which is synergistic. And in all other oral pathogens except S. sanguinis, S. ratti, S. anginosus, and F. nucleatum , it can be seen that FBCI is less than 0.5 and synergistically.

결국 표 2, 3에서 확인되듯이 대부분의 구강병원균에 대하여 후박나무 에탄올 추출물과 항생제의 조합해서 사용했을 경우 단독으로 사용한 것에 비하여 혼합에 따른 상승작용이 있는 것으로 확인되었다.Eventually, as confirmed in Tables 2 and 3, it was confirmed that the combination of ethanol extract and antibiotics of H. oak tree for most oral pathogens had a synergistic effect according to the mixing compared to that used alone.

실험예 3. 시간-사멸 및 성장 억제 곡선 분석(Time-kill and growth inhibition curves assay)Experimental Example 3. Time-kill and growth inhibition curves assay

3-1. 실험준비3-1. Preparation for experiment

실험예 1-1과 동일한 과정으로 실행하였다.It was carried out in the same procedure as in Experimental Example 1-1.

3-2. 실험과정3-2. Experimental process

뮐러 - 힌튼 (Mueller-Hinton) 배지 및 MIC50 농도의 항생제가 포함된 튜브에 구강병원균 균주 현탁액을 접종하여 최종 시험관 내부의 최종 세균 수를 5 ~ 7 ×106 CFU/mL로 유지하였다. The oral pathogen strain suspension was inoculated into a tube containing Mueller-Hinton's medium and an antibiotic of MIC 50 concentration, and the final number of bacteria in the final test tube was maintained at 5 ~ 7 × 10 6 CFU/mL.

그리고 37℃의 혐기성 챔버에서 배양한 후 0, 0.5, 1, 2, 3, 4, 5, 6, 12 및 24 시간 마다 시간의 경과에 따른 생균수계산을 실시하였다. 상기 시험관을 37℃의 혐기성 챔버에서 48시간 동안 원심 분리하여 세척과 멸균 과정을 거친 후 인산염 식염수 (pH 7.3)에서 연속적으로 10배 희석시켜 실험 및 관찰을 수행하였다. Then, after culturing in an anaerobic chamber at 37°C, the number of viable cells was calculated according to the passage of time every 0, 0.5, 1, 2, 3, 4, 5, 6, 12 and 24 hours. The test tube was centrifuged in an anaerobic chamber at 37° C. for 48 hours, washed and sterilized, and then successively diluted 10 times in phosphate saline (pH 7.3) to perform experiments and observations.

후박나무 에탄올 추출물과 항생제의 혼합에 따를 항균활성 효과를 확인하기 위하여 후박나무 에탄올 추출물 단독으로 사용한 것, 후박나무 에탄올 추출물과 앰피실린 및 겐타마이신을 혼합한 것으로 구분하여 시간-세균사멸곡선을 측정하였다. The time-bacterial killing curve was measured by dividing the ethanol extract of Humbak tree as a mixture of the ethanol extract of Humbak tree and the mixture of ampicillin and gentamicin in order to confirm the antimicrobial activity effect of the mixture of the ethanol extract and antibiotics. .

3-3. 실험결과3-3. Experiment result

시간-사멸 및 성장 억제 곡선 분석을 통해 후박나무 에탄올 추출물과 앰피실린 또는 겐타마이신이 함께 사용될 경우, 구강세균 억제효과가 있음이 확인되었다. Time-killing and growth inhibition curve analysis confirmed that when used together with the ethanol extract of H. chinensis and ampicillin or gentamicin, there was an inhibitory effect on oral bacteria.

구체적으로, 도 1 내지 3에 도시된 바와 같이 후박나무 에탄올 추출물이 단독으로 사용될 경우 시간이 지남에 따라 조금씩 사멸되는 것을 알 수 있다. 다만, 후박나무 에탄올 추출물이 앰피실린 또는 겐타마이신과 함께 사용되는 경우, 사멸시간이 훨씬 단축되었고, 사멸속도 역시 굉장히 빠른 것을 알 수 있다. Specifically, as shown in Figs. 1 to 3, it can be seen that when the ethanol extract of Hubak tree is used alone, it dies little by little over time. However, it can be seen that, when the ethanol extract of Humbak tree is used together with ampicillin or gentamicin, the killing time is much shorter, and the killing rate is also very fast.

결국 이는 본 발명의 후박나무 에탄올 추출물은 구강병원균에 대한 항균활성이 있음을 나타낸다. 그리고 후박나무 에탄올 추출물을 단독으로 사용했을 경우에 비하여 앰피실린 및 겐타마이신과 같은 항생제와 혼합하여 사용했을 경우 대부분의 구강병원균에 대하여 항균활성의 상승작용이 탁월한 것을 알 수 있다. Eventually, this indicates that the ethanol extract of the present invention has antibacterial activity against oral pathogens. In addition, it can be seen that the synergistic effect of antimicrobial activity against most oral pathogens is excellent when used in combination with antibiotics such as ampicillin and gentamicin compared to the case of using the ethanol extract of Humbak tree alone.

한편, 본 발명의 후박나무 에탄올 추출물은 특정한 제형에 한정됨이 없이 의약품으로 사용될 수 있고, 특히 구강질환 예방 및 치료제의 유효성분으로 사용가능하다.On the other hand, the ethanol extract of the present invention can be used as a pharmaceutical without being limited to a specific formulation, and in particular, can be used as an active ingredient for oral disease prevention and treatment.

구체적으로, 경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 후박나무 추출물에 적어도 하나 이상의 부형제 예를 들면, 전분, 칼슘카보네이트(calcium carbonate), 수크로스(sucrose) 또는 락토오스(lactose), 젤라틴 등을 섞어 조제된다. 또한, 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 같은 윤활제들도 사용된다. 경구를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데, 흔히 사용되는 단순희석제인 물, 리퀴드 파라핀 이외에 여러가지 부형제 예를 들면, 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다.Specifically, solid formulations for oral administration include tablets, pills, powders, granules, capsules, and the like, and these solid formulations include at least one excipient such as starch, calcium carbonate, It is prepared by mixing sucrose or lactose, gelatin, and the like. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid preparations for oral use include suspensions, liquid solutions, emulsions, syrups, etc. In addition to water and liquid paraffin, which are commonly used simple diluents, various excipients such as wetting agents, sweetening agents, fragrances, and preservatives may be included. .

비경구투여를 위한 형태로는 치약, 구강세정제, 국소 투여제(크림, 연고, 드레싱 용액, 분무제, 기타 도포제등) 등을 들 수 있다. 국소 투여제의 제형의 일 예로는, 유효성분인 후박나무 추출물 또는 구강질환 예방 또는 치료용 조성물을 천연 섬유 또는 합성 섬유로 만든 거즈 등의 담체에 함침시킨 것일 수 있다.Forms for parenteral administration include toothpaste, mouthwash, topical administration (creams, ointments, dressing solutions, sprays, and other coatings). An example of the formulation of the topical administration agent may be a carrier such as gauze made of natural fibers or synthetic fibers impregnated with a composition for preventing or treating oral diseases, or extracts of red oak as an active ingredient.

Claims (10)

삭제delete 삭제delete 삭제delete 삭제delete 삭제delete 후박나무(Machilus thunbergii) 추출물을 유효성분으로 포함하는 구강질환의 예방 또는 개선용 구강위생 조성물로서,
상기 조성물에 항생제 앰피실린(ampicillin) 또는 겐타마이신(gentamicin)이부가되고,
앰피실린(ampicillin)의 경우,
상기 구강질환의 원인균은 Streptococcus mutans ATCC 25175, Streptococcus sobrinus ATCC 27607, Aggregatibacter actinomycetemcomitans ATCC 43717 및 Prevotella intermedia ATCC 49046 중 어느 하나 이상이며,
겐타마이신(gentamicin)의 경우,
상기 구강질환의 원인균은 Streptococcus mutans ATCC 25175, Streptococcus sobrinus ATCC 27607 및 Prevotella intermedia ATCC 49046 중 어느 하나 이상이고,
상기 구강질환은 치아 우식증 질환인 것을 특징으로 하는, 구강질환의 예방 또는 개선용 구강위생 조성물.
As an oral hygiene composition for preventing or improving oral diseases comprising an extract of Machilus thunbergii as an active ingredient,
The antibiotic ampicillin or gentamicin is added to the composition,
In the case of ampicillin,
The causative agent of the oral disease is at least one of Streptococcus mutans ATCC 25175, Streptococcus sobrinus ATCC 27607, Aggregatibacter actinomycetemcomitans ATCC 43717 and Prevotella intermedia ATCC 49046,
In the case of gentamicin,
The causative agent of the oral disease is any one or more of Streptococcus mutans ATCC 25175, Streptococcus sobrinus ATCC 27607 and Prevotella intermedia ATCC 49046,
The oral disease is a dental caries disease, characterized in that, oral hygiene composition for preventing or improving oral disease.
삭제delete 삭제delete 삭제delete 삭제delete
KR1020190086280A 2019-07-17 2019-07-17 COMPOSITION COMPRISING Machilus thunbergii FOR PREVENTING, IMPROVING OR TREATING ORAL DISEASE KR102234310B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020190086280A KR102234310B1 (en) 2019-07-17 2019-07-17 COMPOSITION COMPRISING Machilus thunbergii FOR PREVENTING, IMPROVING OR TREATING ORAL DISEASE

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020190086280A KR102234310B1 (en) 2019-07-17 2019-07-17 COMPOSITION COMPRISING Machilus thunbergii FOR PREVENTING, IMPROVING OR TREATING ORAL DISEASE

Publications (2)

Publication Number Publication Date
KR20210009583A KR20210009583A (en) 2021-01-27
KR102234310B1 true KR102234310B1 (en) 2021-03-31

Family

ID=74238788

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020190086280A KR102234310B1 (en) 2019-07-17 2019-07-17 COMPOSITION COMPRISING Machilus thunbergii FOR PREVENTING, IMPROVING OR TREATING ORAL DISEASE

Country Status (1)

Country Link
KR (1) KR102234310B1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220168219A (en) 2021-06-15 2022-12-23 (주) 바이오에스텍 Oral patch containing as an active ingredient a natural drug extract with antibacterial activity against bacteria that cause oral diseases
KR20230014904A (en) 2021-07-21 2023-01-31 (주) 바이오에스텍 Oral disease patch containing β-(1,6)-branched-(1,3)-glucan produced by the fungus Schizophyllum comune

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101319522B1 (en) 2011-11-08 2013-10-21 롯데제과주식회사 oral health composition for using tooth decay and tooth root disease
KR101335535B1 (en) 2011-12-14 2013-12-02 롯데제과주식회사 Composition for salivary secretion enhancement
KR101704589B1 (en) 2016-07-12 2017-02-08 주식회사 뉴트라팜텍 Composition comprising extracts of Magnolia flower and Magnolia officinlis for preventing or treating periodentitis as an active ingredient

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101344803B1 (en) * 2011-12-02 2013-12-26 주식회사 엘지생활건강 Oral care composition comprising extract of machilus thunbergii and sequestering agent
KR101703269B1 (en) * 2013-06-05 2017-02-06 주식회사 엘지생활건강 Oral care composition comprising Magnolia officinalis extract and bicarbonate
KR20150027352A (en) 2013-08-30 2015-03-12 전남대학교산학협력단 Mouthwash Composition Using Natural Materials and the Manufacturing Method Thereof
KR101713654B1 (en) * 2015-02-13 2017-03-08 (재)남해마늘연구소 Oral composition containing magnolia extract and phytoncide oil
KR101783267B1 (en) * 2015-11-25 2017-09-29 대구보건대학교 산학협력단 A composition comprising alismatis rhizoma extract for preventing, improving or treating periodontal disease
KR20190000955A (en) 2017-06-23 2019-01-04 한양대학교 산학협력단 Composition for preventing or treating periodontal disease comprising extracts of herbal mixture

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101319522B1 (en) 2011-11-08 2013-10-21 롯데제과주식회사 oral health composition for using tooth decay and tooth root disease
KR101335535B1 (en) 2011-12-14 2013-12-02 롯데제과주식회사 Composition for salivary secretion enhancement
KR101704589B1 (en) 2016-07-12 2017-02-08 주식회사 뉴트라팜텍 Composition comprising extracts of Magnolia flower and Magnolia officinlis for preventing or treating periodentitis as an active ingredient

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
치주 질환 예방 및 치료용 소재로서 수종의 생약성분 추출물에 관한 항균, 항염, 항산화 효능 연구, Journal of Dental Hygiene Science, Vol. 10, No. 1, pp. 25-29(2010) 1부.*

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220168219A (en) 2021-06-15 2022-12-23 (주) 바이오에스텍 Oral patch containing as an active ingredient a natural drug extract with antibacterial activity against bacteria that cause oral diseases
KR20230014904A (en) 2021-07-21 2023-01-31 (주) 바이오에스텍 Oral disease patch containing β-(1,6)-branched-(1,3)-glucan produced by the fungus Schizophyllum comune

Also Published As

Publication number Publication date
KR20210009583A (en) 2021-01-27

Similar Documents

Publication Publication Date Title
KR102234310B1 (en) COMPOSITION COMPRISING Machilus thunbergii FOR PREVENTING, IMPROVING OR TREATING ORAL DISEASE
KR102408893B1 (en) Composition for prevention or treatment of oral disease comprising Pueraria Extract
KR102307515B1 (en) COMPOSITION COMPRISING EXTRACT OF Selaginella tamariscina FOR PREVENTING, ALLEVIATING OR TREATING ORAL DISEASE
KR101839612B1 (en) Natural Preservative Composition Containing Plant Extract Complex as Active Ingredient
KR20200139893A (en) Antioxidnat and antibacterial composition comprising Quercus acuta Thunb acorn extract
KR20170103476A (en) Composition for prevention or treatment of oral disease comprising ROSAE LAEVIGATAE Extract
KR102553374B1 (en) Composition for prevention or treatment of dental disease comprising cistanoside A
KR101881636B1 (en) Composition for prevention or treatment of oral disease comprising Pueraria Extract
KR102373594B1 (en) COMPOSITION COMPRISING EXTRACT OF Chrysanthemum indicum FOR PREVENTING, ALLEVIATING OR TREATING ORAL DISEASE
KR20220085035A (en) Composition for improving oral health comprising extracts of Stewartia koreana Nakai and the product comprising the same
KR20210009533A (en) COMPOSITION COMPRISING Trichosanthes kirilowii FOR PREVENTING, IMPROVING OR TREATING ORAL DISEASE
KR102632336B1 (en) Composition for prevention or treatment of dental disease comprising an extract of Daphne genkwa
Manohar et al. Antimicrobial efficacy of white tea mouthwash against bacteria in early childhood caries
KR102511133B1 (en) Composition for Inhibiting Biofilm Formation Comprising Extracts of Coptis chinensis
KR102572961B1 (en) Compositions for preventing, improving or treating periodontal disease containing dendropanax morbifera lev. extracts
KR101436923B1 (en) Antibacterial oral composition containg cirsium sp exctract
KR20100003411A (en) Oral care compositions containing alismae rhizoma extract for preventing tooth decay
KR102417082B1 (en) Composition for prevention or treatment of oral disease comprising Celosia argentea Extract
KR102580941B1 (en) Composition for prevention or treatment of oral disease comprising Qucercetin 3-glucoside
KR20110130131A (en) Antimicrobial composition containing p. nepalensis and p. japonica extracts
KR20170103494A (en) Composition for prevention or treatment of oral disease comprising Melonis Pedicellus Extract
KR20170103482A (en) Composition for prevention or treatment of oral disease comprising Glechoma hederacea extract
KR102642552B1 (en) Composition for prevention or treatment of dental disease comprising gardenoside
Choi et al. A Study on the Antibacterial Effect of ChamaecyparisObtusa Extract on the Causative Agent of Dental Caries
KR20150030123A (en) A composition for treatment of dental caries containing kaurenoic acid

Legal Events

Date Code Title Description
AMND Amendment
E601 Decision to refuse application
AMND Amendment
X701 Decision to grant (after re-examination)
GRNT Written decision to grant